Sodium-glucose co-transporter-2 inhibitors improve cardiovascular outcomes in heart failure with reduced ejection fraction regardless of ischemic etiology

27 August 2021 (08:00 - 20:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Dimitrios Patoulias

Hippokration General Hospital of Thessaloniki, Thessaloniki (Greece)

46 More presentations in this session

Presentation thumbnail

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Doctor A. Sharma (Montreal, CA)

Abstract Slides

Presentation thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Doctor V. Razuk (New York City, US)

Abstract Slides

Presentation thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Doctor G. Steiner-Gager (Vienna, AT)

Abstract Slides

Presentation thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Doctor J. Kolwelter (Erlangen, DE)

Abstract Slides

Presentation thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Doctor M. Senni (Bergamo, IT)

Abstract Slides

Access the full session

Session thumbnail

Congress committee e-posters choice in heart failure

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

You may be interested in

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Congress Session

Which device might help your HFpEF patient?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources